Rachel A. Kudgus

2.5k total citations · 1 hit paper
24 papers, 1.8k citations indexed

About

Rachel A. Kudgus is a scholar working on Oncology, Molecular Biology and Neurology. According to data from OpenAlex, Rachel A. Kudgus has authored 24 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Neurology. Recurrent topics in Rachel A. Kudgus's work include Neuroblastoma Research and Treatments (7 papers), Nanoparticle-Based Drug Delivery (7 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Rachel A. Kudgus is often cited by papers focused on Neuroblastoma Research and Treatments (7 papers), Nanoparticle-Based Drug Delivery (7 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Rachel A. Kudgus collaborates with scholars based in United States, Switzerland and France. Rachel A. Kudgus's co-authors include Priyabrata Mukherjee, Resham Bhattacharya, Sanjib Bhattacharyya, Rochelle R. Arvizo, Karuna Giri, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel, Charles G. Minard and Stacey L. Berg and has published in prestigious journals such as Chemical Society Reviews, Journal of Clinical Oncology and ACS Nano.

In The Last Decade

Rachel A. Kudgus

24 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future

2012 705 citations Rochelle R. Arvizo, Sanjib Bhattacharyya et al. Chemical Society Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel A. Kudgus United States	15	641	568	487	474	351	24	1.8k
Andrew Hsu United States	18	325 0.5×	592 1.0×	533 1.1×	583 1.2×	194 0.6×	61	2.2k
Chen Sun China	20	305 0.5×	590 1.0×	284 0.6×	446 0.9×	155 0.4×	57	1.5k
Jacob W. Myerson United States	23	556 0.9×	579 1.0×	501 1.0×	693 1.5×	77 0.2×	52	2.1k
Hwan‐Jeong Jeong South Korea	30	333 0.5×	693 1.2×	762 1.6×	853 1.8×	215 0.6×	165	2.8k
Yoshinori Koyama Japan	31	811 1.3×	1.2k 2.0×	334 0.7×	1.4k 2.9×	342 1.0×	76	3.4k
Lili Zhao China	29	523 0.8×	672 1.2×	621 1.3×	1.1k 2.4×	269 0.8×	123	2.7k
Michael Chorny United States	25	320 0.5×	891 1.6×	1.2k 2.4×	779 1.6×	146 0.4×	64	2.6k
Yu Chang China	26	570 0.9×	838 1.5×	357 0.7×	845 1.8×	684 1.9×	96	2.7k
François Hindré France	26	267 0.4×	489 0.9×	719 1.5×	584 1.2×	203 0.6×	49	1.8k
Suresh Kumar Balasubramanian United States	15	378 0.6×	272 0.5×	193 0.4×	305 0.6×	123 0.4×	52	1.3k

Countries citing papers authored by Rachel A. Kudgus

Since Specialization

Citations

This map shows the geographic impact of Rachel A. Kudgus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel A. Kudgus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel A. Kudgus more than expected).

Fields of papers citing papers by Rachel A. Kudgus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel A. Kudgus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel A. Kudgus. The network helps show where Rachel A. Kudgus may publish in the future.

Co-authorship network of co-authors of Rachel A. Kudgus

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel A. Kudgus. A scholar is included among the top collaborators of Rachel A. Kudgus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel A. Kudgus. Rachel A. Kudgus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Xinyan, Krishna R. Kalari, Xiaojia Tang, et al.. (2023). Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer. npj Breast Cancer. 9(1). 101–101. 4 indexed citations

Hartono, Stella, Victoria M. Bedell, Sk. Kayum Alam, et al.. (2021). Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury. Mayo Clinic Proceedings. 97(1). 154–164. 14 indexed citations

Chowdhury, Uttio Roy, Rachel A. Kudgus, Tommy A. Rinkoski, et al.. (2021). Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman Primates. Journal of Ocular Pharmacology and Therapeutics. 37(5). 251–260. 9 indexed citations

Geller, James I., Joseph G. Pressey, Malcolm A. Smith, et al.. (2020). ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study. Cancer. 126(24). 5303–5310. 30 indexed citations

Davis, Kara L., Elizabeth Fox, Melinda S. Merchant, et al.. (2020). Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. The Lancet Oncology. 21(4). 541–550. 201 indexed citations

Chowdhury, Uttio Roy, Rachel A. Kudgus, Tommy A. Rinkoski, et al.. (2020). Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits. PLoS ONE. 15(4). e0231841–e0231841. 11 indexed citations

Cole, Kristina A., Sharmistha Pal, Rachel A. Kudgus, et al.. (2019). Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clinical Cancer Research. 26(6). 1213–1219. 48 indexed citations

Geller, James I., Elizabeth Fox, Brian Turpin, et al.. (2018). A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer. 124(23). 4548–4555. 40 indexed citations

Chuk, Meredith K., Brigitte C. Widemann, Charles G. Minard, et al.. (2018). A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Pediatric Blood & Cancer. 65(8). e27077–e27077. 47 indexed citations

10.

Geller, James I., Joseph G. Pressey, Malcolm A. Smith, et al.. (2017). ADVL1522: A phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), and synovial sarcoma: A Children's Oncology Group study.. Journal of Clinical Oncology. 35(15_suppl). 10537–10537. 3 indexed citations

11.

Geller, James I., John P. Perentesis, Xiaowei Liu, et al.. (2017). A phase 1 study of the c‐Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatric Blood & Cancer. 64(11). 10 indexed citations

12.

Geller, James I., John P. Perentesis, Charlotte H. Ahern, et al.. (2014). A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.. Journal of Clinical Oncology. 32(15_suppl). 2627–2627. 1 indexed citations

13.

Kudgus, Rachel A., Chad A. Walden, Renee M. McGovern, et al.. (2014). Tuning Pharmacokinetics and Biodistribution of a Targeted Drug Delivery System Through Incorporation of a Passive Targeting Component. Scientific Reports. 4(1). 5669–5669. 40 indexed citations

14.

Kudgus, Rachel A., Annamária Szabolcs, Jameel Ahmad Khan, et al.. (2013). Inhibiting the Growth of Pancreatic Adenocarcinoma In Vitro and In Vivo through Targeted Treatment with Designer Gold Nanotherapeutics. PLoS ONE. 8(3). e57522–e57522. 25 indexed citations

15.

Arvizo, Rochelle R., Sanjib Bhattacharyya, Rachel A. Kudgus, et al.. (2012). Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chemical Society Reviews. 41(7). 2943–2943. 705 indexed citations breakdown →

16.

Arvizo, Rochelle R., Sanjib Bhattacharyya, Rachel A. Kudgus, et al.. (2012). ChemInform Abstract: Intrinsic Therapeutic Applications of Noble Metal Nanoparticles: Past, Present and Future. ChemInform. 43(27). 1 indexed citations

17.

Khan, Jameel Ahmad, Rachel A. Kudgus, Annamária Szabolcs, et al.. (2011). Designing Nanoconjugates to Effectively Target Pancreatic Cancer Cells In Vitro and In Vivo. PLoS ONE. 6(6). e20347–e20347. 59 indexed citations

18.

Kudgus, Rachel A., Resham Bhattacharya, & Priyabrata Mukherjee. (2011). Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates. Anti-Cancer Agents in Medicinal Chemistry. 11(10). 965–973. 31 indexed citations

19.

Kudgus, Rachel A.. (2010). Gold Nanocrystal Therapeutics: Treatment of Multidrug Resistant Pathogens and Disrupting Protein/Protein Interactions.. NCSU Libraries Repository (North Carolina State University Libraries). 1 indexed citations

20.

Bhattacharyya, Sanjib, Rachel A. Kudgus, Resham Bhattacharya, & Priyabrata Mukherjee. (2010). Inorganic Nanoparticles in Cancer Therapy. Pharmaceutical Research. 28(2). 237–259. 279 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact